These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 15327039

  • 1. Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis.
    Nos C, Sastre-Garriga J, Borràs C, Río J, Tintoré M, Montalban X.
    Mult Scler; 2004 Aug; 10(4):413-6. PubMed ID: 15327039
    [Abstract] [Full Text] [Related]

  • 2. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS.
    Visser LH, Beekman R, Tijssen CC, Uitdehaag BM, Lee ML, Movig KL, Lenderink AW.
    Mult Scler; 2004 Feb; 10(1):89-91. PubMed ID: 14760960
    [Abstract] [Full Text] [Related]

  • 3. Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis.
    Zivadinov R, Zorzon M, De Masi R, Nasuelli D, Cazzato G.
    J Neurol Sci; 2008 Apr 15; 267(1-2):28-35. PubMed ID: 17945260
    [Abstract] [Full Text] [Related]

  • 4. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.
    Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M.
    Neurology; 2001 Oct 09; 57(7):1239-47. PubMed ID: 11591843
    [Abstract] [Full Text] [Related]

  • 5. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M, Sørensen PS, Andersson M, Celius EG, Jongen PJ, Elovaara I, Bartholomé E, Constantinescu CS, Beer K, Garde E, Sperling B.
    Lancet Neurol; 2010 Jul 09; 9(7):672-80. PubMed ID: 20542736
    [Abstract] [Full Text] [Related]

  • 6. A transcranial magnetic stimulation study evaluating methylprednisolone treatment in multiple sclerosis.
    Fierro B, Salemi G, Brighina F, Buffa D, Conte S, La Bua V, Piazza A, Savettieri G.
    Acta Neurol Scand; 2002 Mar 09; 105(3):152-7. PubMed ID: 11886356
    [Abstract] [Full Text] [Related]

  • 7. Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications.
    Fox RJ, Fisher E, Tkach J, Lee JC, Cohen JA, Rudick RA.
    Mult Scler; 2005 Apr 09; 11(2):140-5. PubMed ID: 15794385
    [Abstract] [Full Text] [Related]

  • 8. Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis.
    Perumal JS, Caon C, Hreha S, Zabad R, Tselis A, Lisak R, Khan O.
    Eur J Neurol; 2008 Jul 09; 15(7):677-80. PubMed ID: 18459972
    [Abstract] [Full Text] [Related]

  • 9. Outcome measurement in multiple sclerosis: detection of clinically relevant improvement.
    van Winsen LM, Kragt JJ, Hoogervorst EL, Polman CH, Uitdehaag BM.
    Mult Scler; 2010 May 09; 16(5):604-10. PubMed ID: 20086019
    [Abstract] [Full Text] [Related]

  • 10. A review of interferon use in patients with relapsing remitting multiple sclerosis in the Canterbury region, New Zealand: 2000-2006.
    Byrne S, Mason D.
    N Z Med J; 2012 Feb 24; 125(1350):37-44. PubMed ID: 22382255
    [Abstract] [Full Text] [Related]

  • 11. [Short-term high-dose intravenous methylprednisolone therapy].
    Ohashi T.
    Nihon Rinsho; 2014 Nov 24; 72(11):1995-8. PubMed ID: 25518383
    [Abstract] [Full Text] [Related]

  • 12. The Impact of Methylprednisolone Pulses during Relapses of Multiple Sclerosis on the Kinetics of Anti-Interferon-Beta Antibodies.
    Giantzi V, Karapanayiotides T, Lagoudaki R, Poulatsidou KN, Lourbopoulos A, Daniilidis M, Taskos N, Milonas I, Grigoriadis N.
    Eur Neurol; 2016 Nov 24; 75(1-2):82-8. PubMed ID: 26867030
    [Abstract] [Full Text] [Related]

  • 13. Responsiveness of walking-based outcome measures after multiple sclerosis relapses following steroid pulses.
    Filipović Grčić P, Matijaca M, Lušić I, Čapkun V.
    Med Sci Monit; 2011 Dec 24; 17(12):CR704-10. PubMed ID: 22129902
    [Abstract] [Full Text] [Related]

  • 14. Methylprednisolone stimulated gene expression (GILZ, MCL-1) and basal cortisol levels in multiple sclerosis patients in relapse are associated with clinical response.
    Evangelopoulos ME, Nasiri-Ansari N, Kassi E, Papadopoulou A, Evangelopoulos DS, Moutsatsou P.
    Sci Rep; 2021 Sep 30; 11(1):19462. PubMed ID: 34593869
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of response of multiple sclerosis (MS) relapse to oral high-dose methylprednisolone: usefulness of MS functional composite and Expanded Disability Status Scale.
    Pascual AM, Boscá I, Coret F, Escutia M, Bernat A, Casanova B.
    Eur J Neurol; 2008 Mar 30; 15(3):284-8. PubMed ID: 18290849
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica.
    Yamasaki R, Matsushita T, Fukazawa T, Yokoyama K, Fujihara K, Ogino M, Yokota T, Miyamoto K, Niino M, Nomura K, Tomioka R, Tanaka M, Kawachi I, Ohashi T, Kaida K, Matsui M, Nakatsuji Y, Ochi H, Fukaura H, Kanda T, Nagaishi A, Togo K, Mizusawa H, Murai H, Kira J.
    Mult Scler; 2016 Sep 30; 22(10):1337-48. PubMed ID: 26564994
    [Abstract] [Full Text] [Related]

  • 17. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS.
    Ramo-Tello C, Grau-López L, Tintoré M, Rovira A, Ramió i Torrenta L, Brieva L, Cano A, Carmona O, Saiz A, Torres F, Giner P, Nos C, Massuet A, Montalbán X, Martínez-Cáceres E, Costa J.
    Mult Scler; 2014 May 30; 20(6):717-25. PubMed ID: 24144876
    [Abstract] [Full Text] [Related]

  • 18. Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses.
    Ramo-Tello C, Tintoré M, Rovira A, Ramió-Torrenta L, Brieva L, Saiz A, Cano A, Carmona O, Hervás JV, Grau-López L.
    Mult Scler; 2016 Jan 30; 22(1):117-21. PubMed ID: 26540732
    [Abstract] [Full Text] [Related]

  • 19. Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes.
    Di Gregorio M, Gaetani L, Eusebi P, Floridi P, Picchioni A, Rosi G, Mancini A, Floridi C, Baschieri F, Gentili L, Sarchielli P, Calabresi P, Di Filippo M.
    J Neurol; 2018 Mar 30; 265(3):522-529. PubMed ID: 29327284
    [Abstract] [Full Text] [Related]

  • 20. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
    Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M, ACT Investigators.
    Neurology; 2009 Feb 10; 72(6):535-41. PubMed ID: 19204263
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.